已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

达普 医学 美罗华 内科学 化学免疫疗法 奥图穆马 长春新碱 外科 自体干细胞移植 挽救疗法 胃肠病学 无进展生存期 弥漫性大B细胞淋巴瘤 肿瘤科 进行性疾病 泌尿科 环磷酰胺 移植 淋巴瘤 化疗 生物化学 化学
作者
Gustaaf W. van Imhoff,Andrew McMillan,Matthew J. Matasar,John Radford,Kirit M. Ardeshna,Kazimierz Kuliczkowski,Won-Seog Kim,Xiaonan Hong,Jette Soenderskov Goerloev,Andrew Davies,María Dolores Caballero Barrigón,Michinori Ogura,Sirpa Leppä,Michael Fennessy,Qiming Liao,Bronno van der Holt,Steen Lisby,Anton Hagenbeek
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:35 (5): 544-551 被引量:200
标识
DOI:10.1200/jco.2016.69.0198
摘要

Purpose We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination with cisplatin, cytarabine, and dexamethasone (DHAP) salvage treatment, followed by autologous stem-cell transplantation (ASCT) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients and Methods Patients with CD20+ DLBCL age ≥ 18 years who had experienced their first relapse or who were refractory to first-line R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-like treatment were randomly assigned between three cycles of R-DHAP or O-DHAP. Either O 1,000 mg or R 375 mg/m2 was administered for a total of four infusions (days 1 and 8 of cycle 1; day 1 of cycles 2 and 3 of DHAP). Patients who experienced a response after two cycles of treatment received the third cycle, followed by high-dose therapy and ASCT. Primary end point was progression-free survival (PFS), with failure to achieve a response after cycle 2 included as an event. Results Between March 2010 and December 2013, 447 patients were randomly assigned. Median age was 57 years (range, 18 to 83 years); 17% were age ≥ 65 years; 63% had stage III and IV disease; 71% did not achieve complete response (CR) or experience response for < 1 year on first-line R-CHOP. Response rate for O-DHAP was 38% (CR, 15%) versus 42% (CR, 22%) for R-DHAP. ASCT on protocol was completed by 74 patients (33%) in the O arm and 83 patients (37%) in the R arm. PFS, event-free survival, and overall survival were not significantly different between O-DHAP versus R-DHAP: PFS at 2 years was 24% versus 26% (hazard ratio [HR], 1.12; 95% CI, 0.89 to 1.42; P = .33); event-free survival at 2 years was 16% versus 18% (HR, 1.10; P = .35); and overall survival at 2 years was 41% versus 38% (HR, 0.90; P = .38). Positron emission tomography negativity before ASCT was highly predictive for superior outcome. Conclusion No difference in efficacy was found between O-DHAP and R-DHAP as salvage treatment of relapsed or refractory DLBCL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Rainbow完成签到 ,获得积分10
5秒前
今后应助amber采纳,获得10
9秒前
LLSN完成签到 ,获得积分10
9秒前
12秒前
科研通AI2S应助高高采纳,获得10
14秒前
15秒前
15秒前
LukeLion发布了新的文献求助10
16秒前
十三发布了新的文献求助10
17秒前
18秒前
李爱国应助杏仁核操纵子采纳,获得20
19秒前
amber发布了新的文献求助10
21秒前
LukeLion完成签到,获得积分10
21秒前
拓跋从阳发布了新的文献求助10
26秒前
Zzz_Carlos完成签到 ,获得积分10
29秒前
dpp发布了新的文献求助10
30秒前
buno应助高高采纳,获得10
30秒前
帅气冰菱发布了新的文献求助10
30秒前
33秒前
拓跋从阳完成签到,获得积分10
34秒前
SXR完成签到,获得积分10
35秒前
鹿lu完成签到 ,获得积分10
37秒前
43秒前
杨森omg发布了新的文献求助20
45秒前
NNN7完成签到,获得积分10
46秒前
47秒前
49秒前
追三完成签到 ,获得积分10
53秒前
56秒前
dpp完成签到,获得积分10
56秒前
栗2发布了新的文献求助10
56秒前
海盗船长完成签到,获得积分10
57秒前
58秒前
59秒前
zzz发布了新的文献求助10
1分钟前
程勋航发布了新的文献求助10
1分钟前
辜月十二完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Very-high-order BVD Schemes Using β-variable THINC Method 890
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3256777
求助须知:如何正确求助?哪些是违规求助? 2898945
关于积分的说明 8303121
捐赠科研通 2568188
什么是DOI,文献DOI怎么找? 1394887
科研通“疑难数据库(出版商)”最低求助积分说明 652924
邀请新用户注册赠送积分活动 630631